February 19, 2019
Authored and Edited by Katherine T. Leonard; M. Andrew Holtman, Ph.D.
On February 13, 2019, FDA issued final guidance on developing depot buprenorphine products for treatment of opioid use disorder. FDA new guidance focuses on drug product development and trial design issues relevant to the study of depot buprenorphine products for which submission of a new drug application (NDA) under section 505(b)(2) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) may be appropriate.
Applications for a depot buprenorphine product can be submitted either through an abbreviated new drug application (ANDA) under section 505(j) of the FD&C Act or through an NDA under section 505(b)(2) of the FD&C Act. The regulatory pathway of a new depot buprenorphine product is determined by the characteristics of the investigational product relative to an approved buprenorphine product.
Depot buprenorphine products that are similar to an approved depot product may be submitted under an NDA but may not require efficacy trials. The sponsor may be able to rely on the FDA’s previous findings of efficacy and safety for an approved depot buprenorphine formulation using relative bioavailability and pharmacokinetic studies. Parameters used to determine whether a sponsor needs to conduct efficacy trials can be found in the guidance.
Depot buprenorphine products with novel features relative to approved depot products may be submitted under an NDA but may require efficacy and/or safety studies. The guidance provides details on such a development program and design of efficacy trials for these more novel depot buprenorphine products.
Readers are encouraged to read the final guidance.
Copyright © 2019 Finnegan, Henderson, Farabow, Garrett & Dunner, LLP.
DISCLAIMER: Although we wish to hear from you, information exchanged in this blog cannot and does not create an attorney-client relationship. Please do not post any information that you consider to be personal or confidential. If you wish for Finnegan, Henderson, Farabow, Garrett & Dunner, LLP to consider representing you, in order to establish an attorney-client relationship you must first enter a written representation agreement with Finnegan. Contact us for additional information. One of our lawyers will be happy to discuss the possibility of representation with you. Additional disclaimer information.
Lecture
Patent Protection for Software-Related Inventions in Europe and the USA Training Course
June 5, 2024
Hybrid
INCONTESTABLE® Blog
April 19, 2024
Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.
We use cookies on this website to provide you with the best user experience. By accepting cookies, you agree to our use of cookies. Please note that if you opt not to accept or if you disable cookies, the “Your Finnegan” feature on this website will be disabled as well. For more information on how we use cookies, please see our Privacy Policy.
Finnegan is thrilled to announce the launch of our new blog, Ad Law Buzz, devoted solely to breaking news, developments, trends, and analysis in advertising law.